Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease

Bachanova, V; Marks, D I; Zhang, M-J; Wang, H; de Lima, M; Aljurf, M D; Arellano, M; Artz, A S; Bacher, U; Cahn, J-Y; Chen, Y-B; Copelan, E A; Drobyski, W R; Gale, R P; Greer, J P; Gupta, V; Hale, G A; Kebriaei, P; Lazarus, H M; Lewis, I D
March 2014
Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p658
Academic Journal
The efficacy of reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) is uncertain. We analyzed 197 adults with Ph+ ALL in first complete remission; 67 patients receiving RIC were matched with 130 receiving myeloablative conditioning (MAC) for age, donor type and HCT year. Over 75% received pre-HCT tyrosine kinase inhibitors (TKIs), mostly imatinib; 39% (RIC) and 49% (MAC) were minimal residual disease (MRD)neg pre-HCT. At a median 4.5 years follow-up, 1-year transplant-related mortality (TRM) was lower in RIC (13%) than MAC (36%; P=0.001) while the 3-year relapse rate was 49% in RIC and 28% in MAC (P=0.058). Overall survival (OS) was similar (RIC 39% (95% confidence interval (CI) 27-52) vs 35% (95% CI 27-44); P=0.62). Patients MRDpos pre-HCT had higher risk of relapse with RIC vs MAC (hazard ratio (HR) 1.97; P=0.026). However, patients receiving pre-HCT TKI in combination with MRD negativity pre-RIC HCT had superior OS (55%) compared with a similar MRD population after MAC (33%; P=0.0042). In multivariate analysis, RIC lowered TRM (HR 0.6; P=0.057), but absence of pre-HCT TKI (HR 1.88; P=0.018), RIC (HR 1.891; P=0.054) and pre-HCT MRDpos (HR 1.6; P=0.070) increased relapse risk. RIC is a valid alternative strategy for Ph+ ALL patients ineligible for MAC and MRDneg status is preferred pre-HCT.


Related Articles

  • Imatinib and Chemotherapy in Childhood Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Fuster, Jose Luis; Galera, Ana; Ortuño, Francisco Jose; Sánchez-Salinas, Andrés; Bermúdez, Mar; Llinares, María Esther; Alvarado, Pedro; Olivé, Teresa; Moraleda, Jose María // Asia Pacific Journal of Oncology & Hematology;2009, Vol. 1 Issue 2, p37 

    Philadelphia chromosome positivity is associated with a particularly poor prognosis in childhood acute lymphoblastic leukemia (ALL). Although tyrosine kinase inhibitors such as imatinib in combination with conventional chemotherapy (CT) have proved effective in adult Philadelphia...

  • Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia. Fielding, A K; Goldstone, A H // Bone Marrow Transplantation;Mar2008, Vol. 41 Issue 5, p447 

    ALL in which the Philadelphia (Ph) chromosome is detected is one of the few diseases in which there is almost unequivocal agreement that a matched sibling allogeneic haematopoietic stem cell transplant in first CR is the most appropriate therapy for patients within certain age limits. Extension...

  • Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Pfeifer, H; Wassmann, B; Bethge, W; Dengler, J; Bornhäuser, M; Stadler, M; Beelen, D; Vucinic, V; Burmeister, T; Stelljes, M; Faul, C; Dreger, P; Kiani, A; Schäfer-Eckart, K; Schwerdtfeger, R; Lange, E; Kubuschok, B; Horst, H A; Gramatzki, M; Brück, P // Leukemia (08876924);Jun2013, Vol. 27 Issue 6, p1254 

    Minimal residual disease (MRD) after allogeneic stem cell transplantation (SCT) for Ph+ acute lymphoblastic leukemia (ALL) is predictive of relapse. Imatinib administration subsequent to SCT may prevent relapse, but the role of scheduling and its impact on outcome are not known. In a...

  • Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. Eefting, M; Halkes, C J M; de Wreede, L C; van Pelt, C M; Kersting, S; Marijt, E W A; von dem Borne, P A; Willemze, R; Veelken, H; Falkenburg, J H F // Bone Marrow Transplantation;Feb2014, Vol. 49 Issue 2, p287 

    The prognosis of adult patients with ALL remains unsatisfactory. AlloSCT is associated with a beneficial GVL response mediated by donor T cells. However, GVHD results in substantial mortality and long-term morbidity. T-cell depletion (TCD) of the graft reduces the severity of GVHD, but is...

  • Allogeneic stem cell transplantation outcome in acute lymphoblastic leukemia patients. Alimoghaddam, Kamran; Jahani, Mohamad; Mousavi, Seyyedasadollah; Bahar, Babak; Hamidieh, Amir Ali; Vaezi, Mohammad; Ghaffari, Fatemeh; Jalali, Arash; Sharifi-Aliabadi, Leila; Ghavamzadeh, Ardeshir // International Journal of Hematology-Oncology & Stem Cell Researc;Oct2012, Vol. 6 Issue 4, p1 

    Introduction: Despite achievement to complete remission (CR) with current treatments and new multiple chemotherapeutic agents in Acute Lymphoblastic Leukemia (ALL) patients, the majority of them still relapse during long-term follow-up. The use of post- remission therapy will reduce early...

  • Management of chronic myeloid leukemia in blast crisis. Saußele, S.; Silver, Richard // Annals of Hematology;Apr2015 Supplement, Vol. 94, p159 

    Due to the high efficacy of BCR-ABL tyrosine kinase inhibition (TKI) in chronic phase (CP) chronic myeloid leukemia (CML), the frequency of blast crisis (BC) is greatly reduced compared to the pre-TKI era. However, TKI treatment of BC has only marginally improved the number of favorable...

  • Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Kebriaei, P; Madden, T; Wang, X; Thall, P F; Ledesma, C; de Lima, M; Shpall, E J; Hosing, C; Qazilbash, M; Popat, U; Alousi, A; Nieto, Y; Champlin, R E; Jones, R B; Andersson, B S // Bone Marrow Transplantation;Jan2013, Vol. 48 Issue 1, p26 

    We investigated the administration of i.v. BU combined with melphalan (Mel) in patients with ALL undergoing allogeneic hematopoietic SCT. Forty-seven patients with a median age of 33 years (range 20-61) received a matched sibling (n=27) or matched unrelated donor transplant (n=20) for ALL in...

  • Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect? Breccia, M.; Cannella, L.; Stefanizzi, C.; Carotti, A.; Santopietro, M.; Alimena, G. // Bone Marrow Transplantation;Sep2009, Vol. 44 Issue 5, p331 

    The article reports the case of a 34 year-old woman with chronic myeloid leukemia (CML), who relapsed at the molecular level after haploidentical bone marrow transplantation (BMT) with chronic liver graft versus host disease (GVHD) in November 1996. The patient was treated with high-dose...

  • Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Jiang, H; Xu, L-P; Liu, D-H; Liu, K-Y; Chen, S-S; Jiang, B; Jiang, Q; Chen, H; Chen, Y-H; Han, W; Zhang, X-H; Wang, Y; Wang, J-Z; Wang, F-R; Qin, Y-Z; Lai, Y-Y; Huang, X-J // Bone Marrow Transplantation;Sep2014, Vol. 49 Issue 9, p1146 

    CML treatment with tyrosine kinase inhibitors (TKIs) has improved many patients' prognosis, but during the disease's terminal phase, the blast crisis (CML-BC), has been disappointing. Allo-HSCT is another treatment, but survival rates are still disappointing. Currently, a combination of these...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics